Warburg Research set a €115.00 ($141.98) price objective on Merck KGaA (FRA:MRK) in a research report report published on Friday morning. The brokerage currently has a buy rating on the healthcare company’s stock.
Several other equities research analysts also recently weighed in on the stock. UBS Group set a €120.00 ($148.15) target price on shares of Merck KGaA and gave the company a buy rating in a research note on Friday. DZ Bank restated a buy rating on shares of Merck KGaA in a report on Monday, February 12th. JPMorgan Chase & Co. set a €95.00 ($117.28) price target on shares of Merck KGaA and gave the stock a neutral rating in a report on Monday, February 12th. Kepler Capital Markets set a €115.00 ($141.98) price target on shares of Merck KGaA and gave the stock a buy rating in a report on Wednesday, January 17th. Finally, Sanford C. Bernstein set a €115.00 ($141.98) price target on shares of Merck KGaA and gave the stock a buy rating in a report on Wednesday, January 17th. Eleven investment analysts have rated the stock with a hold rating and eleven have issued a buy rating to the company’s stock. The company has a consensus rating of Buy and a consensus price target of €107.57 ($132.80).
Shares of Merck KGaA (FRA MRK) opened at €83.14 ($102.64) on Friday. Merck KGaA has a 12 month low of €80.50 ($99.38) and a 12 month high of €115.00 ($141.98). The firm has a market cap of $10,700.00 and a price-to-earnings ratio of 19.47.
About Merck KGaA
MERCK Kommanditgesellschaft auf Aktien provides products in the healthcare, life science, and performance materials sectors worldwide. The company offers prescription medicines to treat colorectal cancer, head and neck tumors, multiple sclerosis, infertility, growth hormone disorders, cardiovascular disorders, diabetes, and thyroid disorders; diagnostics and prescription drugs for allergen immunotherapy; and biosimilars for oncology and inflammatory disorders.
Receive News & Ratings for Merck KGaA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merck KGaA and related companies with MarketBeat.com's FREE daily email newsletter.